Method for chromatographic removal of prions

A prion and exchange chromatography technology, applied in the field of chromatographic separation of prions, can solve problems such as destructive activity and denaturation

Inactive Publication Date: 2006-11-08
HEMOGLOBIN OXYGEN THERAPEUTICS
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The extreme conditions required to remove the infectivity of prions are generally incompatible with methods of preserving the useful activity of biomolecules, resulting in denaturation of many biomolecules and essentially destroying their activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 adopts the purification of bovine hemoglobin by anion exchange chromatography

[0029] Preparation of bovine hemoglobin solution

[0030] The preparation of the bovine hemoglobin solution was performed as described in US Patent Application Serial No. 08 / 473,497. First, a sample of bovine whole blood is collected, mixed with the anticoagulant sodium citrate to form a citrated blood solution, and then analyzed for endotoxin levels. After a sample of the blood solution was collected, it was stored at a temperature of 2° C., and then filtered through a 600-mesh sieve to remove large clots and particles.

[0031] The citrated blood solution was then sequentially passed through 800 μm and 50 μm polypropylene filters to remove large debris from the blood solution.

[0032] The red blood cells are then washed to separate extracellular plasma proteins such as BSA or IgG from the red blood cells. When washing red blood cells, first place the blood solution in a di...

Embodiment 2

[0051] Example 2 Confirmation of the method for removing prions from bovine hemoglobin preparations

[0052] The confirmation of the above-mentioned removal method was carried out in a specially registered facility, and the procedures followed were in compliance with the US Food and Drug Administration's laboratory operation regulations (21CFR 58), the procedures stipulated by the British GLP, and the regulations of the Japanese GLP and OECD laboratory operating principles [U.S. Food and Drug Administration Good Laboratory Practice Regulation (21 CFR 58), the United Kingdom GLP Compliance Programme, the Japanese GLP Standard and the OECD Principles of Good Laboratory Practice].

[0053] Various solutions for evaluating the infectivity of sheep dysentery by in vivo assay are: 1) solution of sheep dysentery causative agent for infecting hemoglobin solution; 2) sample A'; 3) sample A"; 4) sample B' ; 5) Sample B".

[0054] In vivo detection

[0055] The detection of sheep dysen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a method for isolating prions from a solution containing prions and at least one other biomolecule, the method comprising passing the solution through an anion-exchange chromatography column and eluting under conditions forming a gradient wherein the prions are Separating from the at least one biomolecule causes said biomolecule to be collected in a different elution fraction than the prion-containing elution fraction. In one embodiment, the gradient is a pH gradient, eg a step gradient. Prions may be pathogens, for example, pathogens of spongiform encephalopathy, such as cortico-striatal-myeloid degeneration, parieto-occipital syndrome, sheep dysentery, bovine spongiform encephalopathy and the like.

Description

technical field [0001] The present invention relates to a method for removing prions from a solution containing prions and hemoglobin, the method comprising the step of passing the solution through an anion exchange chromatographic column under conditions that cause pH gradient elution, wherein the The anion exchange medium comprises silica gel derivatized with cationic groups so that the prions are collected in an eluate fraction which is eluted from an anion exchange chromatography column at pH 6.5 to 8.3, thereby , so that the prions are separated from the collected proteins. Background technique [0002] Spongiform encephalopathies are disorders of the central nervous system in mammals that cause premature dementia and are generally fatal. Some of these encephalopathies involve humans, for example, cortico-striato-myeloid degeneration, kuru, parieto-occipital syndrome, sheep dysentery, bovine spongiform encephalopathy, etc. Although there is strong evidence that these ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/17C07K1/18C07K14/805
CPCC07K1/18C07K14/805
Inventor 玛丽亚·S·加瑞尔罗伯特·A·胡特陈斯威廉姆·R·赖特
Owner HEMOGLOBIN OXYGEN THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap